Abstract Disclosures
Background:
A novel bio-physics based cancer detection technology named Cancer Differentiation Analysis Technology (CDA) has been developed and investigated for cancer treatment prognosis application. Lung cancer treatment prognosis using CDA method was carried out for 3-5 years starting lung cancer diagnosis, followed through surgery, chemotherapy, and remission. CDA’s effectiveness as a tool for lung cancer treatment response was evaluated.
Methods: A total of 686 patients diagnosed with different subtypes of lung cancer were included in this study. Clinical pathological information are shown in Table 1. CDA data were collected in peripheral blood. According to the response evaluation criteria in solid tumors (RECIST) 1.1 standard, the efficacy of 686 patients in response to treatment was evaluated. The correlation between CDA value and patient response to treatment，classified as complete response (CR), partial response (PR), stable disease (SD) , and progressive disease (PD), was evaluated by receiver operating characteristic curve (ROC) and P values.
Results: The lower the CDA value, the better the therapeutic response to treatment (Figs. 1 and 2). CDA value of lung cancer in CR was significantly lower than that in other 3 groups (P ＜0.05) (Fig. 2). CDA value of adenocarcinoma lung cancer (ADC) in CR group was significantly lower than that in SD (stable disease) group. For non-metastatic lung cancer, CDA value in CR group was significantly lower than that in SD group (Fig. 1). The ROC analysis showed that the area under curve (AUC) of lung cancer group, NSCLC group, adenocarcinoma lung cancer group, were 0.756, 0.772, and 0.792, respectively. The AUC of early lung cancer group, and non-metastatic lung cancer group were 0.794, and 0.851, respectively. Above results showed that good correlation between CDA value and lung cancer therapeutic response was observed.
Conclusions: Overall, there is a good correlation between CDA value and lung cancer therapeutic responses, in which CDA value trends down when response becomes more positive. For example, CDA value is the lowest when response is CR, and P values are significant between CR and other responses. CDA could be a potentially viable candidate for evaluating lung cancer therapeutic response.
Meeting: 2022 American Association for Cancer Research
Author(s): Junjie Wu1,2, Zixiu Zou1,2, Xuedong Du3, Xing Tang3, Jie Chen3, Yue Lin3, Sunil Pandit4，Chris Chang Yu3,4#
1 – Ministry of Education Key Laboratory of Contemporary Anthropology and State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China;
2 – Department of Respiratory and Critical Care Medicine, Changhai Hospital, Shanghai, China;
3 – AnPac Bio-Medical Science Co., Ltd., Shanghai, China;
4 – AnPac Technology USA Co., Ltd., Ambler, PA, USA；
